Document is current
Any future updates will be listed below
-
Authors
Bahat, Gulistan https://orcid.org/0000-0001-5343-9795
Catikkas, Nezahat Muge https://orcid.org/0000-0003-2494-1625
Yavuz, Dilek Gogas https://orcid.org/0000-0002-0075-6313
Borman, Pinar https://orcid.org/0000-0003-1212-6797
Guzel, Rengin https://orcid.org/0000-0002-3064-5868
Reginster, Jean Yves https://orcid.org/0000-0001-6290-752X
- License Information
-
More Information
Article History
Received: 23 March 2021
Accepted: 8 November 2021
First Online: 30 November 2021
Declarations
:
: Gulistan Bahat has received a speaker honorarium from Company LILLY and Company AMGEN. Nezahat Muge Catikkas has no conflicts of interest to declare that are relevant to the content of this article. Dilek Gogas Yavuz has no conflicts of interest to declare that are relevant to the content of this article. Pinar Borman has no conflicts of interest to declare that are relevant to the content of this article. Rengin Guzel has received a speaker honorarium from Company Lilly, Company Amgen, and Company Novartis. Jean Yves Reginster has received consulting fees and has served on the paid advisory boards of the following companies: IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, Faes Farma, Rejuvenate Biomed, Samumed, Teva, Theramex, Pfizer, Mithra Pharmaceuticals. He has received lecture fees for speaking upon the invitation of sponsors from the following companies: IBSA-Genevrier, Mylan, CNIEL, Dairy Research Council (DRC), Nutricia, Danone, AgNovos. He has also benefited from grant support from the following companies (institutional): IBSA-Genevrier, Mylan, CNIEL, Radius Health, TRB.
